Perioperative/Adjuvant Atezolizumab in Patients With MSI-high or MMR-deficient Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin-based Chemotherapy - a Phase II Study
Latest Information Update: 18 Dec 2024
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; IMM 101 (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ANTONIO
- 16 Dec 2024 Planned End Date changed from 15 Nov 2026 to 1 Apr 2027.
- 16 Dec 2024 Planned primary completion date changed from 15 Nov 2026 to 1 Apr 2027.
- 16 Dec 2024 Status changed from recruiting to active, no longer recruiting.